|1.||Hamilton, Bronwyn E: 4 articles (03/2013 - 02/2011)|
|2.||Neuwelt, Edward A: 4 articles (03/2013 - 02/2011)|
|3.||Zheng, Jinzi: 3 articles (08/2015 - 03/2009)|
|4.||Muldoon, Leslie L: 3 articles (03/2013 - 02/2011)|
|5.||Rooney, William D: 3 articles (03/2013 - 02/2011)|
|6.||Gahramanov, Seymur: 3 articles (03/2013 - 02/2011)|
|7.||Jaffray, David A: 2 articles (08/2015 - 03/2014)|
|8.||Allen, Christine: 2 articles (03/2014 - 03/2009)|
|9.||Aime, Silvio: 2 articles (05/2013 - 10/2011)|
|10.||Li, Xin: 2 articles (03/2013 - 08/2012)|
08/01/1991 - "Improved enhancement, detection, and delineation of central nervous system (CNS) neoplasms resulting from increased injected doses of gadoteridol have the potential to be clinically significant and may justify the possibly higher cost of increased contrast material dosage. "
01/01/1992 - "The administration of gadoteridol injection provided additional clinically relevant information including improved visualization and delineation of the primary lesion, detection of additional lesions, determination of tumor recurrence and narrowing the list of differential considerations in all 17 enhancing studies as well as in 2 of 5 studies without signal intensity enhancement. "
08/01/1992 - "Gadoteridol injection at doses up to 0.3 mmol/kg is a safe and effective magnetic resonance imaging contrast agent for use in patients with intracranial tumors."
08/01/1992 - "The safety and efficacy of a new, low-osmolal magnetic resonance imaging contrast medium, gadoteridol injection, were evaluated in a phase II, open-label study at doses ranging from 0.05 to 0.30 mmol/kg. Eighty-six patients with a diagnosis of intracranial tumor received gadoteridol injection followed by magnetic resonance imaging. "
03/01/2013 - "Patients were classified as having high rCBV (>1.75), indicating tumor, and low rCBV (≤ 1.75), indicating pseudoprogression, for each contrast agent separately, and with or without contrast agent leakage correction for imaging with gadoteridol. "
|2.||Neoplasm Metastasis (Metastasis)
09/01/1994 - "Region-of-interest analysis of signal intensity measurements showed that lesion contrast (relative to normal brain) improved from 54% at 0.1 mmol/kg to 92% at 0.3 mmol/kg. A 0.3 mmol/kg dose of gadoteridol, administered in a single injection, permits identification of brain metastases not detected at 0.1 mmol/kg. Such information can influence the choice of therapy."
06/01/1994 - "High-dose gadoteridol study may facilitate the care of patients with suspected central nervous system metastasis."
01/01/2013 - "In 69 patients with suspected brain metastasis, we obtained precontrast MR images followed by TCMRA and postcontrast T1-weighted images after administration of 0.1 mmol/kg gadoteridol. "
09/01/2007 - "In 21 consecutive patients with brain metastases, axial images of three sequences at 3T were obtained after administration of gadoteridol. "
08/01/1996 - "Early dynamic magnetic resonance imaging of liver metastases with 0.3 and 0.6 mmol/kg gadoteridol injection."
|3.||Spinal Diseases (Disease, Spinal)
03/01/1993 - "These results indicate excellent safety and efficacy for use of gadoteridol in children with suspected intracranial or spinal disease."
12/01/1991 - "Clinical safety and efficacy of gadoteridol: a study in 411 patients with suspected intracranial and spinal disease."
12/01/1991 - "In this phase III study, 411 adult patients with suspected intracranial or spinal disease underwent magnetic resonance (MR) imaging before and after intravenous injection of 0.1 mmol/kg gadoteridol (gadolinium 1,4,7-tris [carboxymethyl]-10-[2'-hydroxypropyl]-1,4,7,10-tetraazacyclododecane+ ++). "
01/01/1991 - "As part of a phase III clinical trial, 25 patients with suspected intracranial or spinal disease underwent magnetic resonance (MR) imaging before and after intravenous injection of 0.1 mmol/kg Gd-HP-DO3A (1,4,7-tris[carboxymethyl]-10-[2' hydroxypropyl]-1,4,7,10- tetraazacyclododecane), a neutral (nonionic) gadolinium chelate. "
|4.||Breast Neoplasms (Breast Cancer)
08/04/2015 - "Human breast cancer tumors grown in mice were subjected to CA-MSI using Gadoteridol revealing tumor margins and vasculature from the localization of [Gadoteridol+K](+) and [Gadoteridol+Na](+) adducts, respectively. "
07/01/2005 - "The aim of this study was to compare the efficacy of gadoteridol, B22956/1 (a new protein binding blood pool contrast agent), and (Gd-DTPA)37-albumin in detecting, by dynamic contrast-enhanced magnetic resonance imaging (MRI), the effect in vivo of tamoxifen in an experimental model of breast tumor implanted in rats. "
06/01/2009 - "In this work, we examined this assumption by determining the effects of six gadolinium-based contrast agents: Magnevist, Multihance, Omniscan, Optimark, ProHance, and Dotarem, on the Cho peak in phantoms and in a rat model for breast cancer. "
08/01/1996 - "The potential for improvement in liver-lesion conspicuity on early dynamic scans after bolus intravenous gadolinium (Gd) chelate administration was evaluated using gadoteridol (Gd-HP-DO3A; Prohance) at doses of 0.3 and 0.6 mmol/kg. Five New Zealand white rabbits with focal VX-2 adenocarcinoma liver metastases were studied on a 1.5-tesla Siemens Vision scanner. "
|3.||Carrier Proteins (Binding Protein)
|5.||Dihydrotachysterol (AT 10)
|6.||Gadolinium DTPA (Magnevist)
|7.||gadobenic acid (gadobenate dimeglumine)
|2.||Renal Dialysis (Hemodialysis)
|3.||Heterologous Transplantation (Xenotransplantation)